Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms POSITHES
- Sponsors AstraZeneca
- 28 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 11 Nov 2021 New trial record